Literature DB >> 12507822

Clinical and genetic heterogeneity in Mexican patients with ulcerative colitis.

Jesús K Yamamoto-Furusho1, Luis F Uscanga, Gilberto Vargas-Alarcón, Jorge A Ruiz-Morales, Lorena Higuera, Teresa Cutiño, José Manuel Rodríguez-Pérez, Cynthia Villarreal-Garza, Julio Granados.   

Abstract

Ulcerative colitis (UC) is an inflammatory bowel disease of unknown etiology. Genetic factors implied on its onset and severity may include genes located within the class II major histocompatibility complex (MHC) region. The aim of this study was to determine the relationship between human leukocyte antigen (HLA)-DRB1 alleles with the clinical disease patterns of UC in Mexican Mestizo patients. High-resolution HLA typing was performed by polymerase chain reaction-sequence specific oligonucleotide (PCR)-SSO reverse dot blot and PCR-single-strand polymorphism in 67 patients with UC and 99 ethnically matched healthy controls. UC patients overall showed an increased frequency of HLA-DR1 as compared with healthy controls (17.1% versus 5%, [pC = 0.003, OR = 3.9]). Patients with extensive colitis showed increased frequencies of HLA-DR1 (pC = 1 x 10(-10), OR = 13.9), HLA-DRB1*0103 (pC = 1 x 10(-3), OR = 21.7), HLA-DRB1*0102 (pC = 0.007, OR = undetermined), and HLA-DR15 (pC = 1 x 10(-3), OR = 8.5) when compared with healthy controls. We also found a statistically increased frequency of HLA-DR15 in UC patients with extensive colitis compared with UC patients with only distal colitis (18.7% versus 1.8%, pC = 0.03; OR = 12.2). When patients who underwent proctocolectomy were compared with those who did not, an increased frequency of HLA-DRB1*0103 was observed (21.8% versus 4.9%; pC = 0.03; OR = 5.4; 95% confidence interval, 1.39-21.93). Also, patients with proctocolectomy showed increased frequencies of HLA-DR1 (pC = 1 x 10(-3), OR = 24.2) and HLA-DRB1*0103 (pC = 1 x 10(-3), OR = 50.6) when compared with healthy controls. We concluded that HLA-DR1 is associated with genetic susceptibility to UC in the Mexican Mestizo population. HLA-DR15 distinguishes a subgroup of patients with extensive colitis and the HLA-DRB1*0103 allele distinguishes a subgroup of severe form of disease that might require surgical management.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12507822     DOI: 10.1016/s0198-8859(02)00772-3

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  11 in total

1.  Perinuclear anti-neutrophil cytoplasmic antibodies (p-anca) in chronic ulcerative colitis: experience in a Mexican institution.

Authors:  Jesus K Yamamoto-Furusho; Takeshi Takahashi-Monroy; Omar Vergara-Fernandez; Edgardo Reyes; Luis Uscanga
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

Review 2.  Genetics of inflammatory bowel disease: current status and future directions.

Authors:  Thomas D Walters; Mark S Silverberg
Journal:  Can J Gastroenterol       Date:  2006-10       Impact factor: 3.522

Review 3.  Genetic factors associated with the development of inflammatory bowel disease.

Authors:  Jesus-K Yamamoto-Furusho
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

4.  NOD2 gene mutations in ulcerative colitis: useless or misunderstood?

Authors:  Paulo Freire; Ricardo Cardoso; Pedro Figueiredo; Maria M Donato; Manuela Ferreira; Sofia Mendes; Ana Margarida Ferreira; Helena Vasconcelos; Francisco Portela; Carlos Sofia
Journal:  Int J Colorectal Dis       Date:  2014-03-22       Impact factor: 2.571

Review 5.  Genetics of inflammatory bowel disease: the role of the HLA complex.

Authors:  Tariq Ahmad; Sara-E Marshall; Derek Jewell
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

6.  Association of the HLA-DRB1*0701 allele with perinuclear anti-neutrophil cytoplasmatic antibodies in Mexican patients with severe ulcerative colitis.

Authors:  Jesus K Yamamoto-Furusho; Luis Uscanga-Domínguez; Alondra Lopez-Martinez; Julio Granados
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

7.  Genetic predictors of medically refractory ulcerative colitis.

Authors:  Talin Haritunians; Kent D Taylor; Stephan R Targan; Marla Dubinsky; Andrew Ippoliti; Soonil Kwon; Xiuqing Guo; Gil Y Melmed; Dror Berel; Emebet Mengesha; Bruce M Psaty; Nicole L Glazer; Eric A Vasiliauskas; Jerome I Rotter; Phillip R Fleshner; Dermot P B McGovern
Journal:  Inflamm Bowel Dis       Date:  2010-11       Impact factor: 5.325

8.  CBLB502 administration protects gut mucosal tissue in ulcerative colitis by inhibiting inflammation.

Authors:  Yang Xu; Hongxia Dong; Changhui Ge; Yan Gao; Haifeng Liu; Weiguang Li; Chenggang Zhang
Journal:  Ann Transl Med       Date:  2016-08

9.  Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis.

Authors:  Marco M Hefti; David B Chessin; Noam H Harpaz; Randolph M Steinhagen; Thomas A Ullman
Journal:  Dis Colon Rectum       Date:  2009-02       Impact factor: 4.585

Review 10.  Novel genetic markers in inflammatory bowel disease.

Authors:  Lorena Rodriguez-Bores; Gabriela-C Fonseca; Marco-A Villeda; Jesus-K Yamamoto-Furusho
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.